WAT
Waters Corporation
Diagnostics & Research · Healthcare · United States
480.07
close · 2026-10-29
value
35
cheaper than peers35
quality
83
stronger fundamentals83
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| price to book | 3.10× | 71 |
| forward P/E | 29.00× | 53 |
| price to sales | 10.31× | 21 |
| EV to EBITDA | 36.95× | 21 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 91.4% | 98 |
| debt to equity | 36.6% | 60 |
| return on equity | 5.2% | 57 |
| operating margin | 2.8% | 55 |
4 of 4 measures available
Facts
| market cap | $47B |
| free cash flow | -$502.4M |
| employees | 16,000 |
| first trade | 1995-11-17 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-04 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 10.76 | 10.71 | 10.84 | 11.73 |
| free cash flow | $539.8M | $619.6M | $442.2M | $428.2M |
| net income | $642.6M | $637.8M | $642.2M | $707.8M |
| revenue | $3.17B | $2.96B | $2.96B | $2.97B |
| unusual items | $0 | -$11.6M | $0 | -$9.8M |